<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-7063</journal-id>
<journal-title><![CDATA[Enfermería universitaria]]></journal-title>
<abbrev-journal-title><![CDATA[Enferm. univ]]></abbrev-journal-title>
<issn>1665-7063</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional Autónoma de México, Escuela Nacional de Enfermería y Obstetricia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-70632021000300368</article-id>
<article-id pub-id-type="doi">10.22201/eneo.23958421e.2021.3.1096</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Insulinoterapia en pacientes con diabetes mellitus tipo 2. Una revisión narrativa]]></article-title>
<article-title xml:lang="en"><![CDATA[Insulin based therapy in patients with type 2 diabetes mellitus. A narrative review]]></article-title>
<article-title xml:lang="pt"><![CDATA[Insulinoterapia em pacientes com diabetes mellitus tipo 2. Uma revisão narrativa]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Wong]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fuentes-Barría]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilera-Eguía]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Desarrollo Facultad de Salud ]]></institution>
<addr-line><![CDATA[Santiago de Chile ]]></addr-line>
<country>Chile</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Santo Tomás Facultad de Salud ]]></institution>
<addr-line><![CDATA[Santiago de Chile ]]></addr-line>
<country>Chile</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Católica de la Santísima Concepción Facultad de Medicina Departamento de Salud Pública]]></institution>
<addr-line><![CDATA[Concepción ]]></addr-line>
<country>Chile</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>18</volume>
<numero>3</numero>
<fpage>368</fpage>
<lpage>381</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-70632021000300368&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-70632021000300368&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-70632021000300368&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción  La diabetes mellitus tipo 2 (DM2), es una de las enfermedades crónicas no transmisibles que ha aumentado su incidencia en las últimas décadas en todo el mundo, siendo su tratamiento pautas y esquemas de insulinoterapia. No obstante, la gran disponibilidad comercial y el control glucémico atribuido a la insulinoterapia ha generado múltiples confusiones en los usuarios y el personal de salud.  Objetivo  Describir las pautas y esquemas en el tratamiento de la DM2.  Desarrollo  La evolución tecnológica de la insulinoterapia conlleva el uso de múltiples análogos. Dentro de estos destacan los inhalatorios y premezclas por su eficacia en el control glucémico a través del tiempo, considerando las pautas de administración subcutánea en estas premezclas una serie de elementos como la zona de punción, seguridad y uso de pliegues. Dichas pautas han inducido la creación de diversos esquemas de insulinoterapia entre los que se destacan los métodos de acción intensiva y acción móvil, orientados a la simulación de la insulina fisiológica como mecanismo de acción para el control glucémico. La seguridad de estos mecanismos depende del sistema público de salud chileno para la dosificación, administración y control suministrado.  Conclusión  Las pautas y esquemas de insulinoterapia sugieren el uso de análogos de acción prolongada ante hiperglucemia; su uso requiere conocimiento integral de los pacientes y cuidadores con el fin de evitar efectos adversos. Los hallazgos de esta revisión deben ser considerados con cautela al momento de tomar decisiones clínicas producto de las limitaciones metodológicas propias del diseño utilizado.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction  Type 2 diabetes mellitus is one of the non transmissible chronic illnesses which have increased in prevalence during the last decades worldwide. Among the related treatments is the insulin based therapy. Nevertheless, the multiple and diverse controlled and commercial options of this therapy have generated confusion among both the users and health staff.  Objective  To describe some insulin-based therapy approaches to type 2 diabetes mellitus.  Development  The related technological advances have produced new diverse analog forms of insulin-based therapies. Among these, inhaling and blended forms can be highlig- hteddue to their efficacy in glucose control. Among the blended mixture, administration forms are the intensive action and the mobile action ones, which can use a human insulin analog as the key therapy element. The public systems, including the Chilean, have an important security role in the supervision and monitoring of the proper and correct dose administrations.  Conclusion  The diverse forms of insulin-based therapies for patients with type 2 diabetes mellitus include those with prolonged action insulin analogs but their use should be based on integral knowledge in order to avoid adverse effects. The findings of this review should be considered with caution due to the methodological limitations derived from the study design.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução  O diabetes mellitus tipo 2 (DM2), é uma das doenças crônicas não transmissíveis que tem aumentado sua incidência nas últimas décadas no mundo todo, sendo suas diretrizes de tratamento e esquemas de insulinoterapia. No entanto, a grande disponibilidade comercial e o controle glicêmico atribuído à insulinoterapia têm gerado múltiplas confusões em usuários e profissionais de saúde.  Objetivo  Descrever as diretrizes e esquemas no tratamento do DM2.  Desenvolvimento  A evolução tecnológica da insulinoterapia envolve o uso de múltiplos análogos. Dentre estes, os inalantes e pré-misturas destacam-se por sua eficácia no controle glicêmico ao longo do tempo, considerando as orientações de administração subcutânea nessas pré-misturas uma série de elementos como área de punção, segurança e uso de dobras. Essas diretrizes levaram à criação de diversos esquemas de insulinoterapia, dentre os quais se destacam os métodos de ação intensiva e ação móvel, visando simular a insulina fisiológica como mecanismo de ação para o controle glicêmico. A segurança desses mecanismos depende do sistema de saúde pública chileno para a dosagem, administração e controle fornecidos.  Conclusão  Diretrizes e esquemas de insulinoterapia sugerem o uso de análogos de longa ação na hiperglicemia; seu uso requer conhecimento abrangente dos pacientes e cuidadores a fim de evitar efeitos adversos. Os achados desta revisão devem ser considerados com cautela ao tomar decisões clínicas devido às limitações metodológicas do desenho utilizado.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Insulina/administración &amp; dosificación]]></kwd>
<kwd lng="es"><![CDATA[diabetes mellitus tipo 2/terapia]]></kwd>
<kwd lng="es"><![CDATA[hipoglicemiantes/uso terapéutico]]></kwd>
<kwd lng="es"><![CDATA[administración del tratamiento farmacológico]]></kwd>
<kwd lng="es"><![CDATA[resultado del tratamiento]]></kwd>
<kwd lng="es"><![CDATA[Chile]]></kwd>
<kwd lng="en"><![CDATA[Insulin/administration &amp; dosage]]></kwd>
<kwd lng="en"><![CDATA[diabetes mellitus, type 2/therapy]]></kwd>
<kwd lng="en"><![CDATA[hypoglycemic agents/therapeutic use]]></kwd>
<kwd lng="en"><![CDATA[medication therapy management]]></kwd>
<kwd lng="en"><![CDATA[treatment outcome]]></kwd>
<kwd lng="en"><![CDATA[Chile]]></kwd>
<kwd lng="pt"><![CDATA[Insulina/administração &amp; dosagem]]></kwd>
<kwd lng="pt"><![CDATA[diabetes mellitus tipo 2/terapia]]></kwd>
<kwd lng="pt"><![CDATA[hipoglicemiantes/uso terapêutico]]></kwd>
<kwd lng="pt"><![CDATA[conduta do tratamento medicamentoso]]></kwd>
<kwd lng="pt"><![CDATA[resultado do tratamento]]></kwd>
<kwd lng="pt"><![CDATA[Chile]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutiérrez-Rodelo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Roura-Guiberna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Olivares-Reyes]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mecanismos moleculares de la resistencia a la insulina: una actualización]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2017</year>
<volume>153</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>214-28</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carillo-Larco]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Bernabé-Ortiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes mellitus tipo 2 en Perú: una revisión sistemática sobre la prevalencia e incidencia en población general]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2019</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-36</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saeedi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Petersohn]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Salpea]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Malanda]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Karuranga]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Unwin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th ed]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2019</year>
<volume>157</volume>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fullerton]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Siebenhofer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jeitler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Horvath]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Semlitsch]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Berghold]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2018</year>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Abate]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Abate]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Abay]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Abbafati]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Abbasi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the Global Burden of Disease Study 2017]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2018</year>
<volume>392</volume>
<numero>10159</numero>
<issue>10159</issue>
<page-range>1736-88</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Vijayakumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolites as regulators of insulin sensitivity and metabolism]]></article-title>
<source><![CDATA[Nat Rev Mol Cell Biol]]></source>
<year>2018</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>654-72</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2021</year>
<volume>44</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>15-33</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>International Diabetes Federation</collab>
<source><![CDATA[Managing older people with type 2 diabetes. Global Guide-line]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Brussels, Belgium ]]></publisher-loc>
<publisher-name><![CDATA[IDF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Arellano]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro-Contreras]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Padrós-Blázquez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz-Torres]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relación entre autoeficacia, apoyo social, adherencia al tratamiento y HbA1C por nivel de percepción de amenaza en pacientes con DM2]]></article-title>
<source><![CDATA[Nova scientia]]></source>
<year>2020</year>
<volume>12</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>1-22</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivas-Alpizar]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano-Guerrero]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Gutiérrez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía práctica para el personal médico y de enfermería sobre la administración de insulina]]></article-title>
<source><![CDATA[MediSur]]></source>
<year>2005</year>
<volume>3</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar-Bharti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?]]></article-title>
<source><![CDATA[Pharmacol Rep]]></source>
<year>2017</year>
<volume>69</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>959-70</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chatterjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Khunti]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 diabetes]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>389</volume>
<numero>10085</numero>
<issue>10085</issue>
<page-range>2239-51</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ighbariya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin resistance, prediabetes, metabolic syndrome: What should every pediatrician know?]]></article-title>
<source><![CDATA[J Clin Res Pediatr Endocrinol]]></source>
<year>2017</year>
<volume>9</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>49-57</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Bergenstal]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Diamant]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nauck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2015</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>140-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cajigal-Pelegrin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Arguelles-Martínez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Roque-Morgado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Artiles-Pardo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas, epidemiológicas y metabólicas en diabéticos tipo 2 recién diagnosticados con insulina como terapéutica transitoria]]></article-title>
<source><![CDATA[Medi ciego]]></source>
<year>2018</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>4-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gururaj-Setty]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Crasto]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jarvis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Khunti]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New insulins and newer insulin regimens: A review of their role in improving glycaemic control in patients with diabetes]]></article-title>
<source><![CDATA[Postgrad Med J]]></source>
<year>2016</year>
<volume>92</volume>
<numero>1085</numero>
<issue>1085</issue>
<page-range>152-64</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulinoterapia]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2015</year>
<volume>11</volume>
<numero>92</numero>
<issue>92</issue>
<page-range>5510-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freeland]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Farber]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Review of insulin for the treatment of diabetes mellitus]]></article-title>
<source><![CDATA[Home Healthc Now]]></source>
<year>2016</year>
<volume>34</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>416-23</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New insulins and new aspects in insulin delivery]]></article-title>
<source><![CDATA[Can J Diabetes]]></source>
<year>2015</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>335-43</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bejarano-Roncancio]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Almarza-Labarca]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Veloza-Naranjos]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análogos de insulina: relevancia clínica y perspectivas futuras]]></article-title>
<source><![CDATA[Rev. Fac. Med.]]></source>
<year>2012</year>
<volume>60</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>333-41</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinoza-Hernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ocharán-Hernández]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacocinética de la insulina inhalable: ADME (absorción, distribución, metabolismo y excreción)]]></article-title>
<source><![CDATA[Rev Hosp Jua Mex]]></source>
<year>2013</year>
<volume>80</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>54-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Semlitsch]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Engler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Siebenhofer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jeitler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Berghold]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Horvath]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[(Ultra-) long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2020</year>
<volume>11</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1-252</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vidal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Colungo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jansà]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización sobre técnicas y sistemas de administración de la insulina (I)]]></article-title>
<source><![CDATA[Av. diabetol.]]></source>
<year>2008</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>255-69</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frid]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Kreugel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grassi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Halimi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hicks]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New insulin delivery recommendations]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2016</year>
<volume>91</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1231-55</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jansà]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Colungo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización sobre técnicas y sistemas de administración de la insulina (y II)]]></article-title>
<source><![CDATA[Av. diabetol.]]></source>
<year>2008</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>347-54</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaves]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sanabria]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipoglucemia en pacientes con diabetes mellitus en los servicios de urgencias de dos hospitales de Bogotá, 2015-2017]]></article-title>
<source><![CDATA[Revista Colomb. Endocrinología Diabetes Metab]]></source>
<year>2019</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>269-76</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estebanez-Roque]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues-Gomes da Silva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bravo-de Almeida Santos]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Prates-Melo]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fatores de risco associados à hipoglicemia e análise de eventos adversos em uma terapia intensiva]]></article-title>
<source><![CDATA[Texto Contexto Enferm]]></source>
<year>2018</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Titchenell]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Lazar]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Birnbaum]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unraveling the regulation of hepatic metabolism by insulin]]></article-title>
<source><![CDATA[Trends Endocrinol Metab]]></source>
<year>2017</year>
<volume>28</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>497-505</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brunton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology of type 2 diabetes: The evolution of our understanding]]></article-title>
<source><![CDATA[J Fam Pract]]></source>
<year>2016</year>
<volume>65</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Injection technique education in patients with diabetes injecting insulin into areas of lipohypertrophy: A randomized controlled trial]]></article-title>
<source><![CDATA[Diabetes Ther]]></source>
<year>2021</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>813-26</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thewjitcharoen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Prasartkaew]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tongsumrit]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wongjom]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Boonchoo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Butadej]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, risk factors, and clinical characteristics of lipodystrophy in insulin-treated patients with diabetes: An old problem in a new era of modern insulin]]></article-title>
<source><![CDATA[Diabetes Metab Syndr Obes]]></source>
<year>2020</year>
<volume>13</volume>
<page-range>4609-20</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sumikawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sugimori]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors that affect symptoms of injection site infection among Japanese patients who self-inject insulin for diabetes]]></article-title>
<source><![CDATA[Healthcare]]></source>
<year>2021</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<publisher-loc><![CDATA[Basel ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takashima]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is skin disinfection before subcutaneous injection necessary? The reasoning of Certified Nurses in Infection Control in Japan]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2021</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spollett]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Edelman]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Mehner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Walter]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Penfornis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improvement of insulin injection technique: Examination of current issues and recommendations]]></article-title>
<source><![CDATA[Diabetes Educ]]></source>
<year>2016</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>379-94</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tandon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kalra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Balhara]]></surname>
<given-names><![CDATA[YPS]]></given-names>
</name>
<name>
<surname><![CDATA[Baruah]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Chadha]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chandalia]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Forum for injection technique and therapy expert recommendations, India: The Indian recommendations for best practice in insulin injection technique, 2017]]></article-title>
<source><![CDATA[Indian J Endocrinol Metab]]></source>
<year>2017</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>600-17</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robb]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reid]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Laird]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin knowledge and practice: A survey of district nurses in Northern Ireland]]></article-title>
<source><![CDATA[Br J Community Nurs]]></source>
<year>2017</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>138-45</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aschner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin therapy in type 2 diabetes]]></article-title>
<source><![CDATA[Am J Ther]]></source>
<year>2020</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>79-90</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Soidán]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esquemas de inicio de insulinización, ajuste de dosis e intensificación de insulina]]></article-title>
<source><![CDATA[Diabetes Práctica]]></source>
<year>2014</year>
<volume>5</volume>
<numero>^s7</numero>
<issue>^s7</issue>
<supplement>7</supplement>
<page-range>18-22</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): Study protocol for a randomized controlled trial]]></article-title>
<source><![CDATA[Trials]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>365</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Zinman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Connelly]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Retnakaran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of short-term intensive insulin therapy on the incretin response in early type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes Metab]]></source>
<year>2019</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>197-200</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Leu]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Tseng]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sliding-scale insulin used for blood glucose control: A meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Metabolism]]></source>
<year>2015</year>
<volume>64</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1183-92</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Gotfredsen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nørgaard]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of basal-bolus insulin regimens in the inpatient management of non-critically ill patients with type 2 diabetes: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Diabetes Metab Res Rev]]></source>
<year>2017</year>
<volume>33</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Cuervo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Morla]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Jacoiste Asín]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Bisbal-Pardo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Ordoño]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vila-Santos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effective adverse event reduction with bolus-basal versus sliding scale insulin therapy in patients with diabetes during conventional hospitalization: Systematic review and meta-analysis]]></article-title>
<source><![CDATA[Endocrinol Nutr]]></source>
<year>2016</year>
<volume>63</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>145-56</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colunga-Lozano]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Torres]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado-Figueroa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Padilla]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Roman]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2018</year>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krzymien]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ladyzynski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin in type 1 and type 2 diabetes-should the dose of insulin before a meal be based on glycemia or meal content?]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2019</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2021</year>
<volume>44</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>111-24</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Qian]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Watada]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Iwamoto]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Imori]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: Subgroup analysis of the comparison between low mixed insulin and mid mixed insulin as starter insulin for patients with type 2 diabetes mellitus (CLASSIFY Study) randomized trial]]></article-title>
<source><![CDATA[J. Diabetes Investig.]]></source>
<year>2017</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-83</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meece]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basal insulin intensification in patients with type 2 diabetes: A review]]></article-title>
<source><![CDATA[Diabetes Ther]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>877-90</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donnelly]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Doney]]></surname>
<given-names><![CDATA[ASF]]></given-names>
</name>
<name>
<surname><![CDATA[Jennison]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Franks]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rates of glycaemic deterioration in a real-world population with type 2 diabetes]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2018</year>
<volume>61</volume>
<page-range>607-15</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garber]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Handelsman]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Grunberger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahamson]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barzilay]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary]]></article-title>
<source><![CDATA[Endocr. Pract.]]></source>
<year>2020</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>107-39</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Serifovski]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Herz]]></surname>
<given-names><![CDATA[AMH]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gaede]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hommel]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of advanced carbohydrate counting and automated insulin bolus calculators in type 2 diabetes: The BolusCal2 study, an open-label, randomised controlled trial. In: 54th EASD Annual Meeting of the European Association for the Study of Diabetes]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2018</year>
<volume>61</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ulloa-Sabogal]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Mejia-Arciniegas]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Plata-Uribe]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Noriega-Ramírez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quintero-Gómez]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Grimaldos-Mariño]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proceso de enfermería en la persona con diabetes mellitus desde la perspectiva del autocuidado]]></article-title>
<source><![CDATA[Rev. cuba. enferm.]]></source>
<year>2017</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>404-17</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Silva]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Calisto-Mansilla]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Valdebenito-Vivar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Merino-Jara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión integrativa de autoeficacia en el uso de insulina en personas diagnosticadas con diabetes tipo 2]]></article-title>
<source><![CDATA[Rev. iberoam. Educ. investi. Enferm.]]></source>
<year>2019</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>30-9</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallardo-Zanetta]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Franco-Vivanco]]></surname>
<given-names><![CDATA[PV]]></given-names>
</name>
<name>
<surname><![CDATA[Urtubey]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencia de pacientes con diabetes e hipertensión que participan en un programa de telemonitoreo]]></article-title>
<source><![CDATA[Rev CES Med]]></source>
<year>2019</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-41</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bächler]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mujica]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Orellana]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cáceres]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Carrasco]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia de un programa educativo estructurado en población diabética chilena]]></article-title>
<source><![CDATA[Rev. méd. Chile]]></source>
<year>2017</year>
<volume>145</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>181-7</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lutfiyya]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Tomai]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Frogner]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cerra]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zismer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Parente]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does primary care diabetes man- agement provided to Medicare patients differ between primary care physicians and nurse practitioners?]]></article-title>
<source><![CDATA[J Adv Nurs]]></source>
<year>2017</year>
<volume>73</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>240-52</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
